Associations of Inflammatory Markers with AIDS and Non-AIDS Clinical Events After Initiation of Antiretroviral Therapy: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

Overview

Journal J Acquir Immune Defic Syndr

Specialty Infectious Diseases

Date 2013 Oct 15

PMID 24121755

Citations 42

Authors

Grace A McComsey

Douglas Kitch

Paul E Sax

Camlin Tierney

Nasreen C Jahed

Kathleen Melbourne

Belinda Ha

Todd T Brown

Anthony Bloom

Neal Fedarko

Eric S Daar

Affiliations

Soon will be listed here.

Abstract

Background: The association of inflammatory biomarkers with clinical events after antiretroviral therapy initiation is unclear.

Methods: A5202 randomized 1857 treatment-naive subjects to abacavir/lamivudine or tenofovir-DF/emtricitabine with efavirenz or atazanavir/ritonavir. Substudy A5224s measured inflammatory biomarkers on subjects with available plasma from baseline and week 24 or 96. An exploratory analysis of the association of high-sensitivity C-reactive protein, interleukin-6 (IL-6), soluble receptors of tumor necrosis factor α (sTNF)-RI, sTNF-RII, TNF-α, soluble vascular cellular adhesion molecules (sVCAM-1), and soluble intercellular adhesion molecules (sICAM-1) with times to AIDS and to non-AIDS events used Cox proportional hazards models.

Results: Analysis included 244 subjects; 85% men and 48% white non-Hispanic with median age 39 years, HIV-1 RNA of 4.6 log10 copies per milliliter, and CD4 of 240 cells per microliter. Overall, 13 AIDS events (9 opportunistic infections, 3 AIDS-cancers, and 1 recurrent bacterial pneumonia) and 18 non-AIDS events (6 diabetes, 4 cancers, 3 cardiovascular, and 5 pneumonias) occurred. Higher baseline IL-6, sTNF-RI, sTNF-RII, and sICAM-1 were significantly associated with increased risk of AIDS-defining events. Adjustment for baseline HIV-1 RNA did not change results, whereas adjusting for baseline CD4 count left only sTNF-RI and sICAM-1 significantly associated with increased risk. Time-updated values of IL-6, sTNFR-I and II, and sICAM-1 were also associated with an increased risk. For non-AIDS events, only higher baseline high-sensitivity C-reactive protein was significantly associated with increased risk, whereas higher IL-6 was marginally associated with higher risk. Analyses of time-updated biomarker values showed tumor necrosis factor α to be significantly associated with increased risk, even after adjustment for antiretroviral therapy, and CD4 count or HIV-1 RNA.

Conclusions: Higher levels of several inflammatory biomarkers were independently associated with increased risk of AIDS and non-AIDS events.

Citing Articles

Changes to inflammatory markers during 5 years of viral suppression and during viral blips in people with HIV initiating different integrase inhibitor based regimens.

Funderburg N, Huang S, Cohen C, Ailstock K, Cummings M, Lee J Front Immunol. 2024; 15:1488799.

PMID: 39600696 PMC: 11590120. DOI: 10.3389/fimmu.2024.1488799.

Impact of the first-line antiretroviral therapy on soluble markers of inflammation in cohort of human immunodeficiency virus type 1 in Moroccan patients: a prospective study.

Haddaji A, Ouladlahsen A, Lkhider M, Bensghir R, Jebbar S, Hilmi S Arch Microbiol. 2023; 205(6):223.

PMID: 37154966 DOI: 10.1007/s00203-023-03574-0.

Ramadan fasting reduces high-sensitivity C-reactive protein among HIV-infected patients receiving antiretroviral therapy.

Widhani A, Yunihastuti E, Setiati S, Witjaksono F, Karjadi T Front Nutr. 2023; 9:964797.

PMID: 36687703 PMC: 9852883. DOI: 10.3389/fnut.2022.964797.

The Many Faces of Immune Activation in HIV-1 Infection: A Multifactorial Interconnection.

Mazzuti L, Turriziani O, Mezzaroma I Biomedicines. 2023; 11(1).

PMID: 36672667 PMC: 9856151. DOI: 10.3390/biomedicines11010159.

Clinical factors and outcomes associated with immune non-response among virally suppressed adults with HIV from Africa and the United States.

Noiman A, Esber A, Wang X, Bahemana E, Adamu Y, Iroezindu M Sci Rep. 2022; 12(1):1196.

PMID: 35075147 PMC: 8786968. DOI: 10.1038/s41598-022-04866-z.

References

Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, Lane H . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5(10):e203. PMC: 2570418. DOI: 10.1371/journal.pmed.0050203. View

Kalayjian R, Machekano R, Rizk N, Robbins G, Gandhi R, Rodriguez B . Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis. 2010; 201(12):1796-805. PMC: 2873127. DOI: 10.1086/652750. View

Neaton J, Neuhaus J, Emery S . Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010. Curr Opin HIV AIDS. 2010; 5(6):480-90. PMC: 3079321. DOI: 10.1097/COH.0b013e32833ed75d. View

Zangerle R, Steinhuber S, Sarcletti M, Dierich M, Wachter H, Fuchs D . Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals. Int Arch Allergy Immunol. 1998; 116(3):228-39. DOI: 10.1159/000023949. View

Ross A, ORiordan M, Storer N, Dogra V, McComsey G . Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis. 2010; 211(2):492-8. DOI: 10.1016/j.atherosclerosis.2010.04.008. View

McComsey G, Kitch D, Sax P, Tebas P, Tierney C, Jahed N . Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis. 2011; 53(2):185-96. PMC: 3165963. DOI: 10.1093/cid/cir324. View

Peduzzi P, Concato J, Feinstein A, Holford T . Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995; 48(12):1503-10. DOI: 10.1016/0895-4356(95)00048-8. View

Ross A, Rizk N, ORiordan M, Dogra V, El-Bejjani D, Storer N . Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009; 49(7):1119-27. PMC: 3895473. DOI: 10.1086/605578. View

McComsey G, Kitch D, Daar E, Tierney C, Jahed N, Melbourne K . Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS. 2012; 26(11):1371-85. PMC: 3560932. DOI: 10.1097/QAD.0b013e328354f4fb. View

10.

Overton E, Kitch D, Benson C, Hunt P, Stein J, Smurzynski M . Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis. 2013; 56(10):1471-9. PMC: 3693493. DOI: 10.1093/cid/cit053. View

11.

Medrano F, Leal M, Arienti D, Rey C, Zagliani A, Torres Y . Tumor necrosis factor beta and soluble APO-1/Fas independently predict progression to AIDS in HIV-seropositive patients. AIDS Res Hum Retroviruses. 1998; 14(10):835-43. DOI: 10.1089/aid.1998.14.835. View

12.

Feldman J, Goldwasser P, Holman S, DeHovitz J, Minkoff H . C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defic Syndr. 2003; 32(2):210-4. DOI: 10.1097/00126334-200302010-00014. View

13.

Boulware D, Hullsiek K, Puronen C, Rupert A, Baker J, French M . Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011; 203(11):1637-46. PMC: 3096784. DOI: 10.1093/infdis/jir134. View

14.

Havlir D, Torriani F, Schrier R, Huang J, Lederman M, Chervenak K . Serum interleukin-6 (IL-6), IL-10, tumor necrosis factor (TNF) alpha, soluble type II TNF receptor, and transforming growth factor beta levels in human immunodeficiency virus type 1-infected individuals with Mycobacterium avium complex disease. J Clin Microbiol. 2001; 39(1):298-303. PMC: 87718. DOI: 10.1128/JCM.39.1.298-303.2001. View

15.

Brown T, Tassiopoulos K, Bosch R, Shikuma C, McComsey G . Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care. 2010; 33(10):2244-9. PMC: 2945167. DOI: 10.2337/dc10-0633. View

16.

McComsey G, Kitch D, Daar E, Tierney C, Jahed N, Tebas P . Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy.... J Infect Dis. 2011; 203(12):1791-801. PMC: 3100514. DOI: 10.1093/infdis/jir188. View

17.

Triant V, Meigs J, Grinspoon S . Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr. 2009; 51(3):268-73. PMC: 2763381. DOI: 10.1097/QAI.0b013e3181a9992c. View

18.

Drain P, Kupka R, Msamanga G, Urassa W, Mugusi F, Fawzi W . C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting. AIDS. 2007; 21(15):2067-75. PMC: 4005838. DOI: 10.1097/QAD.0b013e32826fb6c7. View

19.

Brown T, McComsey G, King M, Qaqish R, Bernstein B, da Silva B . Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009; 51(5):554-61. DOI: 10.1097/QAI.0b013e3181adce44. View